KRAS and hepatocellular carcinoma: Wild-type KRAS organoid lines of HCC were sensitive to the EGF receptor inhibitor AZD8931, while organoids harboring mutated KRAS were resistant, suggesting guidance for personalized medicine based on tumor heterogeneity29.